400 results on '"Braicu, Elena Ioana"'
Search Results
2. Correction: Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer
3. Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy
4. Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer
5. Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ)
6. ERRα promotes glycolytic metabolism and targets the NLRP3/caspase-1/GSDMD pathway to regulate pyroptosis in endometrial cancer
7. Prognostic value of regulatory T cells and T helper 17 cells in high grade serous ovarian carcinoma
8. Olaparib in an ovarian cancer patient with end-stage renal disease and hemodialysis
9. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
10. Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium
11. A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer
12. LRP1B—a prognostic marker in tubo-ovarian high-grade serous carcinoma
13. HE4 as a serum biomarker for the diagnosis of pelvic masses: a prospective, multicenter study in 965 patients
14. Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer
15. ASO Visual Abstract: Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome, and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer (HGSOC). A Multicenter, Retrospective Study of the Ovarian Cancer Therapy—Innovative Models Prolong Survival (OCTIPS) Consortium
16. Gene expression markers in peripheral blood and outcome in patients with platinum‐resistant ovarian cancer: A study of the European GANNET53 consortium.
17. Loss of copy numbers of retrotransposons (HERVK) on chromosome 7p11.2 impacts EGFR (Epidermal Growth Factor Receptor)‐induced phenotypes for platinum sensitivity and long‐term survival in ovarian cancer—A study from the OVCAD consortium.
18. Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study.
19. Prevalence of human papillomavirus detection in ovarian cancer: a meta-analysis
20. ESGO–SIOPE guidelines for the management of adolescents and young adults with non-epithelial ovarian cancers
21. Side Effects from Cancer Therapies and Perspective of 1044 Long-Term Ovarian Cancer Survivors—Results of Expression VI–Carolin Meets HANNA–Holistic Analysis of Long-Term Survival with Ovarian Cancer: The International NOGGO, ENGOT, and GCIG Survey
22. PO013/#435 Role of lymphadenectomy (LND) in advanced ovarian cancer (OC) -A subgroup analysis of the patients excluded from the original lion trial (the charité cohort)
23. PO009/#424 Innovative academic homologous recombination deficiency tests available in advanced ovarian cancer: the European ENGOT initiative
24. #384 First interim analysis of the SCOUT-1 Study (NOGGO Ov54, NCT04830709): a non-interventional study to evaluate treatment patterns and longterm outcome in patients with newly diagnosed advances ovarian cancer
25. 7 Gutartige Erkrankungen der weiblichen Genitalorgane
26. The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer: A meta-analysis
27. Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium
28. Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism
29. Lymphovascular space invasion and Ki67 as predictors of lymph node metastasis in primary low grade serous ovarian cancer
30. Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation
31. ERRα promotes glycolytic metabolism and targets the NLRP3/caspase-1/GSDMD pathway to regulate pyroptosis in endometrial cancer
32. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
33. Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy–Innovative Models Prolong Survival (OCTIPS) Consortium
34. Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).
35. Supplementary figure legends and the title and notes of supplementary tables from A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer
36. Supplementary Figure S4 from A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer
37. Supplementary Table 1 from Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer
38. Supplementary Table S2 from A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer
39. Supplementary Table 4 from Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer
40. Supplementary information from Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses
41. Supplementary Table 2 from Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer
42. Supplementary Figures and Tables from Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas
43. Supplementary Table S2 from Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas
44. Supplementary Figure Legends from Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas
45. Supplementary Methods from Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas
46. Current Treatment Practices and Prognostic Factors in Early-Stage Ovarian Cancer—An Analysis of the NOGGO/JAGO
47. 7 Gutartige Erkrankungen der weiblichen Genitalorgane
48. Clinical Outcome After Completion Surgery in Patients With Ovarian Cancer: The Charite Experience
49. TP034/#1534 Randomized phase III trial on niraparib-TSR-042 (Dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, primary peritoneal cancer platinum resistant patients: nitche trial(MITO 33)
50. TP038/#1408 Rucaparib maintenance after bevacizumab maintenance following carboplatin based first line chemotherapy in ovarian cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.